TNXP Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital

Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital
EN
07/10/2020

Underlying

TNXPTonix Pharmaceuticals Holding Corp

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tonix Pharmaceuticals Holding Corp

 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and...

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia set to launch in November Tonmya is the first new FDA-approved medicine for fibromyalgia in more than 15 years Cash and cash equivalents of $190.1 million reported as of September 30, 2025; current cash runway expected to fund operations into the first quarter of 2027 CHATHAM, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated...

November 10, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Con...

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference CHATHAM, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biotechnology company, today announced that Seth Lederman, M.D., Tonix’s Chief Executive Officer, will be presenting at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 10:00 AM ET. Investors interested in arranging a meeting with the Company’s management during the conference should contact their Stifel representative. A webcast of ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Collaboration with Massachusetts Gener...

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026   Novel immunomodulatory regimen designed to reduce calcineurin inhibitor exposure and improve outcomes Dimeric Fc-modified mAb TNX-1500 selectively targets cell-associated CD40L with once-monthly dosing CHATHAM, N.J., Nov. 04, ...

November 4, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025 CHATHAM, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial biopharmaceutical company announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe 2025, being held November 3–5, 2025, in Vienna, Austria. The Company’s presentation will take place on Tuesday, November 4, at 3:00 p.m. CET in Presenting Company Theater 1 at the Vienna Congress and Convention Center. Dr. Lede...

October 28, 2025 1 EN
 PRESS RELEASE
Free
TNXP Tonix Pharmaceu...

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl S...

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence Tonmya demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT studyTreatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally acting, non-opioid analgesic and therapeutic option for adults with fibromyalgia CHATHAM, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch